LCD L39396: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Noridian
Policy LCD-L39396 · Hematology
New LCD requires billing team review.
Code intelligence
C85.90 reimbursement alerts
Policy changes, MAC LCD updates, and CMS guidance matched to code C85.90.
Elevated code riskView ICD-10 detail
Signal breakdown
4 shown · 4 total in platform
Risk: Elevated
0
Critical
0%
1
High
25%
3
Routine
75%
0
Low
0%
New this month
—
alerts added in last 30 days
Effective soon
—
no upcoming deadlines
Routine
LCD L39398: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin's and Non-Hodgkin's Lymphoma with B-cell or T-cell Origin — Noridian
Policy LCD-L39398 · Hematology
New rules for transplant billing could affect reimbursements.
Proposed LCD DL39314: Off-Label Use of Intravenous Immune Globulin (IVIG) — NGS
Policy LCD-DL39314 · Allergy/Immunology
Impact of off-label IVIG use on Medicare billing.
LCD L38920: Off-label Use of Rituximab and Rituximab Biosimilars — CGS
Policy LCD-L38920 · Oncology
Prepare for billing changes on Rituximab off-label use.
Audit documentation
Building an audit file that includes C85.90?
The Tripwire Audit Pack exports 12 months of Hematology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.
Get the Hematology audit pack — $349One-time purchase · not a subscription